Here's Why Inhibrx Stock Is on the Move Today
Shares of Inhibrx (NASDAQ: INBX), a clinical-stage biotechnology company, jumped when the market opened today. Investors excited about the company's latest clinical trial readout pushed the stock 26.8% higher as of 11:29 a.m. on Tuesday.
Today, Inhibrx reported top-line data from a phase 1 trial with INBRX-101. This is the company's specialized version of alpha-1 antitrypsin (AAT), a protein that protects lung tissue.
Source Fool.com